Why The Pfizer COVID-19 Vaccine Development Is Reason for Optimistic - a podcast by The Quint
from 2020-11-12T12:54
::
::
As the total cases of coronavirus in the world touch 52 million, with India's overall tally alone standing at 8.6 million, in this dire time, the progress in the COVID vaccine candidate being developed by American drugmaker Pfizer and its German partner BioNTech is certainly a very welcoming news.
The pharma giants have revealed that their COVID-19 vaccine candidate — BNT162b2 was more than 90 percent efficient against infections in participants without prior infections.
Although the results are yet to be approved by US drug regulator FDA, the pharma company said it was hopeful about being able to produce up to 50 million vaccine doses globally by the end of 2020 and up to 1.3 billion doses in 2021.
But what does this announcement exactly mean? Are we close to developing a COVID vaccination? How long before it becomes available in India? Tune in to The Big Story!
Producer and Host: Shorbori Purkayastha
Producer and Host: Shorbori Purkayastha
Editor: Shelly Walia
Music: Big Bang Fuzz
Listen to The Big Story podcast on:
Apple: https://apple.co/2AYdLIl
Saavn: http://bit.ly/2oix78C
Google Podcasts: http://bit.ly/2ntMV7S
Spotify: https://spoti.fi/2IyLAUQ
Deezer: http://bit.ly/2Vrf5Ng
Further episodes of The Big Story
Further podcasts by The Quint
Website of The Quint